One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate.
Down 43% from all-time highs, Structure Therapeutics is a pre-revenue clinical-stage biopharma company that trades at a massive discount to consensus price target estimates.
Novo Nordisk has received both good and bad news recently when it comes to weight loss and diabetes drugs. So, where does the firm stand now?
Eli Lilly is still a smart pick, but these two stocks could grow more in the near term.
Becoming the next Novo Nordisk is a long shot, but it's more likely than it sounds.
Analysts who follow the start-up drugmaker think its stock has a chance to soar, but that doesn't mean it's right for you.
Structure Therapeutics has a long way to go before beating Wegovy.
With weight-loss drugs gaining traction, which biopharma stock wins?
Structure Therapeutics is a clinical-stage weight-loss company that is poised to gain traction in a rapidly expanding addressable market.